Abergel A et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 16: 1219-1227, 2004.

Abrescia N et al. Sexual transmission of HCV in sexually infected HIV women. Fourteenth International AIDS Conference, Barcelona, abstract C11013, 2002.

Ahmad, S. Death in HIV infected inpatients in the HAART era: an evaluation of mortality in an inner city hospital. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, Abstract 300, 2001.

Aizen, K et al. Acute hepatitis C (HCV) in a cohort of HIV-positive homosexual men- patient characteristics, risk factors and outcomes. Ninth Annual Meeting of the British HIV Association, Manchester, abstract P45, 2003.

Alary M et al. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort of men who have sex with men. Am J Public Health 95: 502-505, 2005.

Alatrakchi N et al. A tale of two viruses: hepatitis C in the age of HAART. Lancet 362: 1687-1688, 2003.

Alberti A et al. Short statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients. J Hepatol 42(5): 615-624, 2005.

Amin J et al. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 5: 174-179, 2004.

Anderson KB et al. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 39: 1507-1513, 2004.

Antonucci G et al. Effect of hepatitis C virus genotype on CD4⁺ T cell count in a cohort of antiretroviral-naive HIV-1-infected individuals. J Infect Dis 192: 703-704, 2005a.

Antonucci G et al. Role of hepatitis C virus viraemia and hepatitis C virus genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 40: e101-e109, 2005b.

Aranzabal L et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Clin Infect Dis 40(4): 588-593, 2005.

Augenbraun M et al. Incident hepatitis C virus in women with human immunodeficiency virus infection. Clin Infect Dis 37: 1357-1364, 2003.

Backus LI et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 39: 613-619, 2005.

Bani-Sadr F et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 40: 47-52, 2005.

Bellobuono A et al. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomised clinical trial. J Viral Hepatol 4: 185-191, 1997.

Benhamou Y et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatology 30: 1054-1058, 1999.

Benhamou Y et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34: 283-287, 2001.

Berggren R et al. False-negative hepatitis C antibody is associated with low CD4 counts in HIV/HCV-coinfected patients. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 562, 2001.

Bica I et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32: 492-497, 2001.

Bhagani S et al. Acute hepatitis C virus (HCV) in a cohort of HIV-positive men: outcomes and response to pegylated interferon-alpha2b and ribavirin. Tenth Anniverary BHIVA Conference, Cardiff, abstract 020, 2004.

Bochet M et al. Efficacy and tolerance of IFNa; plus ribavirin for chronic hepatitis C in HIV-infected patients. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 574, 2001.

Bonacini M et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18: 2039-2045, 2004.

Bonfanti P et al. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS 19: 1433 - 1434, 2005.

Bonnet F et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy (HAART). Aquitaine Cohort (France), 1998-1999. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 299, 2001.

Braitstein P et al. The impact of the hepatitis C virus on CD4 cell response post initiation of HAART among a population-based HIV treatment cohort. Antivir Ther 8, S235-S236, 2003.

Braitstein P et al. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS. 18(17): 2221-2234, 2004.

Bräµ N et al. Safety of peginterferon alfa-2a (PEGASYS) 180 mcg weekly plus ribavirin (RBV) 800 mg daily in HIV/HCV coinfection compared to HCV monoinfection. Fifteenth International AIDS Conference, Bangkok, abstract 3311, 2004.

Bräµ N et al. Hepatocellular carcinoma in 40 HIV/HCV-coinfected versus 50 HCV-monoinfected patients: North American HCC in HIV Study Group. Third IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract . TuPe1.1C17, 2005.

Browne RE et al. Increasing incidence of acute hepatitis C in HIV-positive men secondary to sexual transmission: a new epidemic? Ninth Annual Meeting of the British HIV Association, Manchester, abstract 016, 2003.

Cacoub P et al. Mortality among human immunodeficiency virus infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis 32: 1207, 2001.

Camino N et al. Early HCV-RNA clearance in HIV/HCV coinfected patients who begin treatment with pegylated interferon plus ribavirin. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract H-1753, 2004.

Camma C et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patients data. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30: 801-807, 1999.

Cargnel A et al. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther. 10(2): 309-17, 2005.

Carrat F et al. Pegylated interferon Alfa-2b vs standard interferon Alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Amer Med Assoc 292: 2839-2848, 2004.

Catalano D et al. Maternal-fetal transmission of HCV. Role of HIV as a risk factor. Minerva Ginecologica 51: 117-119, 1999.

Chaillou S et al. COPERE : A randomized open label trial of pegylated-interferon alfa-2b(PEG-IFN) plus ribavirine (RIB) vs PEG-IFN monotherapy in hepatitis C coinfected patients. 24 weeks preliminary study. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract H-828, 2003.

Chaix ML et al. Phylogenetic analysis reveals a cluster of genotype 4 HCV transmitted by sexual intercourse in HIV-1 infected men. 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 34, 2004.

Chaix ML et al. Homosexually transmitted HCV acute infection related to a clustered genotype 4 HCV in HIV-1-infected men and inefficacy of early antiviral therapy. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 122, 2005.

Cherner M et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64: 1343-1347, 2005.

Chihrin S et al. Exposure to lopinavir/r is a risk factor for grade 3 / 4 elevation of ALT in HIV and hepatitis B (HBV) and/or C (HCV) coinfected patients. Fifteenth International AIDS Conference, Bangkok, abstract MoPeB3281, 2004.

Chung R et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16: 1915-1923, 2002.

Chung R et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New Engl J Med 351: 451-459, 2004.

Coll S et al. Treatment of hepatitis C HIV-co-infected patients with interferon: controlled study. 50th Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, abstract 153, 1999.

Cooper CL et al. Evaluation of the benefits of HAART in HIV-HCV co-infected subjects. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract H-826, 2003.

C󲤯ba J et al Driving under the influence of minimal hepatic encephalopathy. Hepatology 39: 599-601, 2004.

Cowling BJ et al. Virologic and immunologic response to antiretroviral therapy among HIV patients co-infected with hepatitis C virus (HCV) - analysis of a 6,401 HIV patient cohort. Fifteenth International AIDS Conference, Bangkok, abstract 3300, 2004.

Craib KJP et al. Evidence of sexual transmission of hepatitis C virus (HCV) in a cohort of homosexual men. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 561, 2001.

Crespo M et al. 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 428, 2004.

Cummings KJ et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously non-responsive to interferon. JAMA 285: 193-199, 2001.

Daar ES et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in haemophiliacs. J Infect Dis 183: 589-595, 2001.

Darby SC et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 350: 1425-1431, 1999.

Davis GL for the International Hepatitis Interventional Therapy Group. Interferon Alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339: 1493-1499, 1998.

Davis GL et al. Long-term continuous recombinant interferon ALFA-2B (Intron A) versus repeated 24 week cycles for disease suppression in IFN-relapsers with chronic hepatitis. 50th Annual Meeting of the American Association for the Study of Liver Disease, Dallas, abstract 627, 1999.

DeJesus E et al. Safety of a fosamprenavir/ritonavir (FPV/r) containing regimen over 120 weeks in HIV-1 infected therapy-naﶥ adults with or without hepatitis B (HBV) and/or C (HCV) co-infection. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract TuPe1.1C03, 2005.

den Brinker M et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14: 2895-2902, 2000.

de Vera ME et al. Progression and treatment of recurrent hepatitis after liver transplantation in patients co-infected with HIV. Hepatology 38: S161A, 2003.

Dieterich D et al. Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV-co-infected patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract 105, 1999.

Dieterich D et al. Lack of Hepatotoxicity Associated With Nonnucleoside Reverse Transcriptase Inhibitors. J. Acquir Immune Defic Syndr 29:340-345, 2002.

Dieterich D et al. The safety/efficacy of protease inhibitors (PIs) in hepatitis C (HCV) co-infected patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract H-831, 2003.

Di Marco V et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha-2b interferon plus ribavirin for 6 or 12 months. 50th Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, abstract 570, 1999.

Di Martino V et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS. 16: 441-445, 2002.

D'Oliveira A et al. Prevalence and sexual risk of hepatitis C virus infection when human immunodeficiency virus was acquired through sexual intercourse among patients of the Lyon University Hospitals, France, 1992-2002. J Viral Hepatitis 12(3): 330-332, 2005.

Dominguez S et al. The HEPADOSE study: evaluation of protease inhibitors and non nucleoside analogue plasma concentrations in HIV/HCV and HIV-infected patients. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract WePp0305, 2005.

Dorrucci, M et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS 18: 2313-2318. 2004.

Duncombe CJ et al. Impact of chronic viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort, Thailand, 1996-2001. Fifteenth International AIDS Conference, Bangkok, abstract 1327, 2004.

Duong M et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 27: 245-250, 2001.

Esteban R. Treatment of chronic hepatitis C in HCV/HIV coinfected patients. Fourteenth International AIDS Conference, Barcelona, abstract MoOrB113, 2002.

European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 41(1): 45-51, 2005

Farel C et al. Serious ophthalmic pathology compromising vision in HCV/HIV coinfected patients treated with peginterferon alpha-2b and ribavirin. AIDS 18: 1805-1809, 2004.

Farmer Miller M et al. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 41: 713-720, 2005.

Flexman JM et al. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12: 2289-2293, 1999.

Fonquernie L et al. Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients. HIV Med 5: 385-390, 2004.

Frassetto LA et al. Two-year evaluation of the interactions between antiretroviral medication and cyclosporine in HIV+ liver and kidney transplant recipients. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract P540, 2003.

Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 347: 975-982, 2002.

Fultz S et al. Survival in patients coinfected with HIV and hepatitis C in the HAART era. Fifteenth International AIDS Conference. Bangkok, abstract MoPeB3318, 2004.

Garcia-Samaniego J et al. Long-term response to interferon therapy in HIV infected patients with chronic hepatitis C. Twelfth World AIDS Conference, Geneva, abstract 20, 1998.

Garcia-Samaniego J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J of Gastroenterol 96: 179-183, 2001.

George SL et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 31:152-162, 2002.

Gerlach et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterol 25: 80-88, 2003.

Gibb D et al. Early report: Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 356: 904-907, 2000.

Ghosn J et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 5: 303-306, 2004.

Gilleece, Y et al. Evaluate changes in incidence and treatment of acute hepatitis C infection. Fifteenth International AIDS Conference, Bangkok, abstract 3296, 2004.

Gilleece Y et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 40: 41-46, 2005.

Gö´º HM et al. A cluster of acute hepatitis C virus infection among men who have sex with men results from contact tracing and public health implications. AIDS 19: 969-974, 2005.

Graham C and Koziel MJ. Why should hepatitis C affect immune reconstitution in HIV-1-infected patients? Lancet 356:1865, 2000.

Greub G et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356: 1800-1805, 2000.

Hagan H et al. Sharing of drug preparation equipment as a risk factor for Hepatitis C. American J Publ Health 91: 42-46, 2001.

Haley RW et al. The tattooing paradox: Are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Ann Intern Med 163: 1095-1098, 2003.

Hammer GP et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997 - 2000. Sex Transm Dis 30: 919-924, 2003.

Harcourt GC et al. Longitudinal analysis of CD8 T-cell responses to HIV and heptatitis C virus in a cohort of co-infected haemophiliacs. AIDS 19: 1135-1143, 2005.

Heathcote EJ et al. Peginterferon alpha-2b in patients with chronic hepatitis C and cirrhosis. New Engl J Med 343: 1673-1680, 2000.

Herring BL et al. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 190: 1396-1402, 2004.

Hershow RC et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis 176: 414-420, 1997.

Hershow RC et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS and death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 40: 859-867, 2005

Hezode C et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatol 42(1): 63-71, 2005.

Hickman IJ et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53: 413-419, 2004.

Hinrichsen H et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterol 127:1347-1355, 2004.

Hoffman-Terry M et al. Hepatotoxicity of non-nucleoside reverse transcriptase inhibitor (NNRTI) containing. Thirteenth International AIDS Conference, Durban, abstract B2148, 2000.

Hoffman-Terry M et al. Risk of HAART-induced hyperglycemia in HIV/HCV-coinfected patients. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 619, 2001.

Hoffman-Terry M, Khalili M, Bernstein D et al. Safety and efficacy of 40 Kda peginterferon alfa-2b (Pegasys) in the treatment of pts co-infected with HIV and HCV: Preliminary results from a randomized, multicenter trial. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1725, 2002.

Hopkins S et al. HIV-HCV co-infection: to treat or not to treat. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 973, 2003.

Hor T et al. Concomitant ddI/d4T and IFN (standard or pegylated)/ribavirin treatments may induce a high risk of mitochondrial toxicity in HIV/HCV infected Patients (ANRS HCO2-RIBAVIC study). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1735, 2002.

Houghton M et al. Prospects for vaccination against the hepatitis C virus. Eleventh International Symposium on Viral Hepatitis and Liver Disease, Sydney, symposium 4, 2003.

Izopet J et al. Antiviral effect of interferon alpha-2a (IFN alpha) in patients infected with both HIV and HCV. Twelfth World AIDS Conference, Geneva, abstract 32103, 1998.

Jaeckel E et al. Treatment of Acute Hepatitis C with Interferon Alfa-2b. New Engl J Med 345: 1452-1457, 2001.

Jauncey M et al. Clearance of hepatitis C virus after newly acquired infection in drug users. J Infect Dis 190: 1270-1274, 2004.

Jeffers L et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. 39: 1702-1708, 2004.

John M et al. Hepatitis C virus -associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12: 2289-2293, 1998.

Justice AC et al. HIV survival: liver function tests independently predict survival. Fourteenth International AIDS Conference, Barcelona, abstract MoOrB1058, 2002.

Kaiser S and others. Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon and ribavirin using daily consensus interferon and ribavirin. 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 173, 2004.

Kelleher T. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 43(1): 78-84, 2005.

Kenny-Walsh E et al. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. New Engl J Med 340: 1228-1233, 1999.

Klein MB et al. Hepatitis C (HCV) co-infection is associated with increased morbidity and mortality among HIV-infected patients. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 308, 2001.

Klein MB et al. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33: 365-372, 2003.

Kottilil S et al. Hepatitis C viral load (VL) increases after initiation of HAART and control of HIV in co-infected individuals. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1737, 2002.

Kramer JR et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 100(1):56-63, 2005.

Kraus MR et al. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatitis. 12(1): 96-100, 2005

Lackner C. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatol 41(6): 1376-1382, 2005.

Laguno M et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 18: F27-F36, 2004.

Landau AOL et al. Long-term efficacy of combination therapy with interferon-alpha2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 15: 2149-2155, 2001.

Lafeuillade A et al. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357: 280-281, 2001.

Lascar RM et al. Outcome of acute hepatitis C in HIV-positive homosexual men. Ninth Annual Meeting of the British HIV Association, Manchester, abstract 017, 2003.

Leevy C et al. Interim results of a pilot study of the combination of type 1 (IFN ALFACON 1) and type 2 (IFN GAMMA 1B) interferons in chronic hepatitis patents who have failed to respond to peg-interferon alpha 2a plus ribavirin. 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 530, 2004.

Lesens O et al. Hepatitis C virus is related to progressive liver disease in HIV-positive hemophiliacs and should be treated as an opportunistic infection. Journal of Infectious Diseases 179(5): 1254-1258, 1999.

Lissen E et al. Histological response to peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (Copegus) in patients with HIV-HCV co-infection: results of the AIDS Pegasys Ribavirin International Co-Infection Trial (APRICOT). 55th Annual Meeting of the American Society for the Study of Liver Diseases, Boston, abstract 174, 2004 .

Lincoln D et al. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 4: 241-249, 2003.

Lyra A et al. Infection with Hepatitis C Virus Genotype 4 in the United States. Journal of Clinical Gastroenterol 38: 68-71, 2004.

Macias J et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18: 767-74, 2004.

Mangia A et al. Peginterfereon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617, 2005.

Manns MP et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.

Marcellin P et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127: 875-881, 1997.

Marincovich B et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 79: 160-162, 2003.

Mariné­‚arjoan E et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 18: 2163-2170, 2004.

Martin J et al. Impact of hepatitis C in HIV-infected individuals in an urban center in Madrid, Spain. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 572, 2001.

Martin-Carbonero L and Soriano V. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. AIDS 19: 621-623, 2005.

Martin-Carbonero L et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 17: 1467-1471, 2001.

Martin-Carbonero L et al. Histological damage in liver biopsy specimens from 492 HIV-HCV co-infected patients: a European collaborative study. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract P830, 2003.

Martin-Carbonero L et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 38: 128-133, 2004.

Martinot-Peignoux M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 29: 214-223, 1999.

Mauss S et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 18: 21-25, 2004.

McArthur J. Risk factors and determinants for HIV-associated sensory neuropathies: is hepatitis C a modifier? Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 27, 2004.

McHutchison JG et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 339: 1485-1492, 1998.

McHutchison JG et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterol 119: 1317-1323, 2000.

Mehta SH et al. The effect of HAART and HCV infection on the development of diabetes mellitus among HIV-infected persons. J Acquir Immune Defic Syndr 33: 577-584, 2003.

Mendel I et al. Lack of activity of the protease inhibitors on the hepatitis C virus replication in HIV-coinfected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-28, 1998.

Mendes-Correa MCJ et al. Risk factors associated to hepatitis C infection among patients with HIV infection. Fourteenth International AIDS Conference, Barcelona, abstract ThPeC7493, 2002.

Meraviglia P et al. Lopinavir/ritonavir treatment in HIV antiretroviral experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 5: 334-351, 2004.

Mok J et al. When does mother to child transmission of hepatitis C virus occur? Obstet Gynecol Surv 60: 572-574, 2005.

Mohsen AH et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52: 1035-1040, 2003.

Monforte Ade A et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 28: 114-123, 2001.

Monga HK et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33: 240-247, 2001.

Monto A et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatol 39: 826-834, 2004.

Monto A et al. Hepatic steatosis in HIV/hepatitis C coinfection: Prevalence and significance compared with hepatitis C monoinfection. Hepatol 42(2): 310-316, 2005.

Moreno L et al. Outcome and safety of IFN/RBV in HCV/HIV coinfected patients with advanced fibrosis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract V-784, 2004.

Msellati P et al. Prevalence of hepatitis B and C viruses and HCV genotypes in HIV-positive and negative pregnant women in Abidjan, Ivory Coast (West Africa). Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 974, 2003.

Muir AJ et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. New Engl J Med 350: 2265-2271, 2004.

Myers RP et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 17: 721-725, 2003.

Nasti G et al. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha 2b and ribavirin combination therapy. J Acquir Immune Defic Syndr 26: 299-300, 2001.

National Institutes of Health. Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements. 19(3), 2002.

Neff GW et al. Update on orthotopic liver transplantation in human immunodeficiency syndrome (HIV) + patients with coinfection. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1741, 2002.

Nelson M et al. Increasing incidence of acute hepatitis C in HIV positive men secondary to sexual transmission, epidemiology and treatment. Ninth European AIDS Conference, Warsaw, abstract F12/3, 2003.

Nelson M et al. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection. HIV Med 6: S96-S106, 2005.

Norris Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 10: 1271-1278. 2004.

Nunez M et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27: 426-431, 2001.

Nunez M et al. Efficacy and safety of pegInterferon-alpha 2a plus ribavirin for the treatment of hepatitis C in HIV coinfected patients: the PRESCO trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract V-1148, 2004.

Njouom R et al. Seroprevalence of HCV among HIV-positive compared to HIV-negative pregnant women in Yaounde, Cameroon. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 967, 2003.

OGrady J et al. Guidelines for liver transplantation in patients with HIV infection. HIV Med 6: S149-S153, 2005.

Ortega E et al. An open-label, multicenter study of the efficacy and safety of peginterferon alfa-2a(40KD) (PEGASYS), alone, or in combination with ribavirin (COPEGUS), in patients with HIV/HCV co-infection. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract H-829, 2003.

Parra-Ruiz J et al. IT78047 trial. A randomized, multicentre study of pegylated interferon alfa 2A plus two different doses of ribavirin in the treatment of patients with chronic hepatitis C and HIV infection. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 971, 2003.

Pasquier C et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. J Med Virol 69: 344-349, 2003.

Patroni A et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials 3: 451-461, 2002.

Payen JL et al. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe d'Etude et de Traitement du Virus de l'Hepatite C (Get.Vhc). Hepatology 28: 1680-1686, 1998.

Perez-Cano R et al. Evolution of hepatitis C virus viral load in relationship of HIV viral load in patients who responded to antiretroviral therapy. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-27, 1998.

Perez-Olmeda M et al. Interferon +ribavirin in HIV+ patients with chronic hepatitis C. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 284, 2000.

Perez-Olmeda M et al. Hepatitis C virus (HVC) relapses following the end of anti-HCV therapy are more frequent in HIV-co-infected patients. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract, 2003.

Piasecki BA et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 40: 892-899, 2004.

Pineda J et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatol 41(4): 779-789, 2005

Polgreen PM et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 5: 144-150, 2004.

Poynard T et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832, 1997.

Poynard T et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 352: 1426-1432, 1998.

Puoti M et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 181: 2033-2036, 2000.

Puoti M et al. Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV-infected patients: prospective cohort study. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 576, 2001a.

Puoti M et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 183: 134-137, 2001b.

Puoti M et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 32: 259-267, 2003.

Quereda C et al. Features and biochemical markers of histological severity in HIV-HCV coinfected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1722, 2002.

Quereda C et al. The role of liver biopsy in the management of chronic hepatitis C in patients infected with HIV. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 982, 2003.

Qurishi N et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362: 1708-1713, 2003.

Ragni MV et al. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 180: 2027-2029, 1999.

Ragni MV et al. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 183: 1112-1115, 2001.

Ragni MV et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 188: 1412-1420, 2003.

Rancinan C et al. Does hepatitis C virus (HCV) coinfection modify survival in HIV patients on combination of antiretrovirals? Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 570, 2001.

Rauch A et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 41: 395-402, 2005.

Reddy KR et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33: 433-438, 2001.

Reesink HW et al. Initial results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Digestive Disease Week, Chicago, abstract 527, 2005.

Reichard O et al. Randomised, double-blind, placebo-controlled trial of interferon with and without ribavirin for chronic hepatitis C. Lancet 351: 83-87, 1998.

Reisler RB et al. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 34: 379-386, 2003.

Robek M et al. Lambda interferon inhibits hepatitis B and C virus replication. J Virology 79(6): 3851-3854, 2005.

Rockstroh J et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis: 192(6):992-1002, 2005.

Rodrí§µez-Torres M et al. Predictability of sustained virological response at week 4 in HIV-HCV co-infected patients treated with peginterferon alfa-2a (40KD) (Pegasys) + ribavirin (Copegus) in the AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT), Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, abstract H-1751, 2004a.

Rodrí§µez-Torres M et al. Retreatment with Peg-IFN-alfa2a and RBV of co-infected (HIV-HCV) non-responders to IFN, achieves improved liver histology in both sustained viral responders and non-responders. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 826, 2004b.

Roland M et al. 1- to 3-year outcomes in HIV-infected liver and kidney transplant recipients. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 953, 2005.

Rooney G and Gilson R. Sexual transmission of hepatitis C virus infection. Sex Transm Infect 74: 399-404, 1998.

Rosenthal E et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients France in 2001 (MORTAVIC 2001 Study). Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 87, 2003.

Rufi G et al. Orthotopic liver transplantation in 15 HIV-1-infected recipients: evaluation of Spanish experience in the HAART era (2002-2003). Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 827, 2004.

Rutschmann OT et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 177: 783-785, 1998.

Sabin CA et al. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet 360: 1546-1551, 2002.

Salmon-Ceron D et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42(6): 799-805, 2005.

Santantonio T et al. Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42(3): 329-333, 2005.

Sauleda S et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 34: 1035-1040, 2001.

Schaefer M et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42(6): 793-798, 2005.

Schafer, DF and Sorrel MF. Conquering hepatitis C, step by step. New England J Med 343: 1723-1724, 2000.

Smith DM et al. Symptomatic hyperlactatemia during a large hepatitis C treatment trial in HIV/HCV co-infected participants on stable antiretroviral therapy. Fourteenth International AIDS Conference, Barcelona, abstract MoOrB1059, 2002.

Soler M et al. Antiviral efficacy and HCV resistance to ISIS 14803, an antisense oligonucleotide inhibitor of HCV. Eleventh International Symposium on Viral Hepatitis and Liver Disease, Sydney, abstract WE4-04, 2003.

Soriano V et al. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS 11: 400-401, 1997.

Soriano V et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 15: 1-4, 1999.

Soriano V et al. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. First International AIDS Society Conference in HIV Pathogenesis and Treatment, Buenos Aires, abstract 42, 2001a.

Soriano V et al. Mortality due to chronic viral liver disease among patients infected with HIV. Clin Infect Dis 33: 1793-1795, 2001b.

Soriano V et al. HIV-1 progression in hepatitis-C-infected drug users. Lancet: 1361-1362, 2001c.

Soriano V et al. Editorial review: care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 16: 813-828, 2002.

Soriano V et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 9: 505-509, 2004a.

Soriano V et al. Care of patients with hepatitis C and HIV co-infection. AIDS 18: 1-12. 2004b.

Soto B et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26: 1-5, 1997.

Soza A et al. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol 43(1):67-71, 2005.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&term=%22Heller+T%22%5BAuthor%5D

Sprinz E et al. Hepatitis C virus infection in a southern Brazilian cohort of HIV-infected patients. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 978, 2003.

Stebbing J et al. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis: 41(6): 906-11, 2005.

Sterling RK et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 32: 30-37, 2003.

Sulkowski M et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B infection. Journal JAMA 283: 74-80, 2000.

Sulkowski M et al. Effect of HCV coinfection on HIV disease progression and survival in HIV-infected adults. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 34, 2001.

Sulkowski M et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35: 182-189, 2002a.

Sulkowski M et al. Hepatitis C and progression of HIV disease. JAMA 288: 199-206, 2002b.

Sulkowski M et al. Final results of daily vs 3-times weekly interferon alpha-2b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons: a multi-center, randomized open-label study. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 841, 2003.

Sulkowski M et al. Unexpected significant liver disease among HIV/HCV-co-infected persons with minimal fibrosis on initial liver biopsy. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 121, 2005a.

Sulkowski M et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 19: 585-592, 2005b.

Sulkowski M et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 39: 504-506, 2005c.

Tahan V et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 100(4): 821-824,l 2005.

Tedaldi EM et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36: 363-367, 2003a.

Tedaldi EM et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: The Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 36: 1313-1317, 2003b.

Teicher E et al. Liver transplantation in HIV-HCV co-infected patients. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 828, 2004.

Thomas DL et al. The natural history of hepatitis C virus infection. JAMA 284: 450-456, 2000.

Thomopoulos K wt al. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol & Hepatol 17(2): 149-154, 2005.

Tor J et al. Chronic hepatitis C in HIV-infected patients: effects of coinfection and HAART. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 566, 2001.

Torriani FJ et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 351: 438-450, 2004.

Turner J et al. Hepatitis C virus coinfection and HIV-infected patients in the UK collaborative HIV cohort. Twelfth Annual Conference of the British HIV Assosiation, Brighton, abstract 014, 2006.

Uberti-Foppa C et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 33: 146-152, 2003.

Uberti-Foppa. Fibrosis damage in liver biopsy specimens from 354 HIV-HCV co-infected patients: role of persistently normal alanineaminotrasferase. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 814, 2004.

Van Asten L and Prins, M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 18: 2313-2318. 2004.

Vandelli C. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Amer J Gastroenterol 5: 885-889. 2004.

Vogel M et al. Orthotopic liver transplantation in HIV-positive patients: outcome of 10 patients from the Bonn Cohort. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 931, 2005.

Weisbord JS et al. Prevalence and risk factors for hepatitis C virus infection among STD clinic clientele in Miami, Florida. Sex Transm Infect 79: 1-5, 2003.

Weis N et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort survey. Clin Infect Dis 42: 1481-1487, 2006.

Weisz K et al. Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV coinfected patients. 12 month follow-up. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 283, 2000.

Williams IT et al. Hepatitis C virus (HCV)-infected sex partners as a source for infection among persons with acute hepatitis C. Eleventh International Symposium on Viral Hepatitis and Liver Disease, Sydney, session WB5, 2003.

Wirth S et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatol 41(5): 1013-1018, 2005.

Wong JB et al. Projecting the prognosis of hepatitis fibrosis in HIC-HCV co-infection. Hepatology 38: S425A, abstract 551, 2003.

Yang Y et al. Hepatitis C and neuropsychological function in treatment naive HIV-1-infected subjects - A5097s baseline analysis. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 26, 2004.

Yoo TW et al. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. Hemophilia Growth and Development Study. J Infect Dis 191: 4-10, 2005.

Zaltron S et al. Treatment of hepatitis C with recombinant alpha 2a (RIFNA2A) in HIV seropositives in the HAART era. Thirteenth International AIDS Conference, Durban, abstract B659, 2000.

Zanini B et al. The optimal duration of treatment for HIV-infected patients with chronic heptatitis C (CHC) and genotype 2 or 3 is 48 weeks: results of a randomised controlled trial. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract MoPpLB0103, 2005.

Zein N et al. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study . J Hepatol 42(3): 315-322, 2005.

Zeuzem S et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl J Med 343: 1666-1672, 2000.

Ziol M et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis. Hepatol 41(1): 48-54, 2005.